Company News
Lupin Licenses Oncology Programs for 82.2% Kaveri Stake
Lupin Inc. USA grants exclusive perpetual license for two oncology programs, LNP7457 and LNP8701, to Kaveri Therapeutics.
Transaction valued at USD 1.6 million gives Lupin Inc. USA an 82.2% equity sta
